Etodolac

DRUG8 trials

Sponsors

The University of Tokyo, Astellas Pharma Inc, MEDRx USA, Inc., IPCA Laboratories Ltd., Flavia Pardo Salata Nahsan

Conditions

Ankle SprainsEpithelial Ovarian CancerFallopian Tube CancerFastingHealthyMedicaments Substances in Therapeutic UseOvarian CancerOvarian Carcinoma

Phase 1

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition

CompletedNCT01746719

IPCA Laboratories Ltd.Fasting

Start: 2012-10-31End: 2012-12-31Updated: 2012-12-11

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition

CompletedNCT01749228

IPCA Laboratories Ltd.Healthy

Start: 2012-10-31End: 2012-12-31Updated: 2012-12-13

Phase 3

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

CompletedNCT01118572

Astellas Pharma IncPost Operative Pain

Start: 2010-02-28End: 2010-11-30Updated: 2014-10-15

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

CompletedNCT01198834

MEDRx USA, Inc.Ankle Sprains

Start: 2010-09-30End: 2011-06-30Updated: 2018-01-17

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

TerminatedNCT03127592

Apsen Farmaceutica S.A.Pain, Acute

Start: 2020-10-05End: 2022-07-26Updated: 2023-02-09

Phase 4

Etodolac and Post-bleaching Sensitivity

CompletedNCT02881619

Flavia Pardo Salata NahsanMedicaments Substances in Therapeutic Use

Start: 2014-11-30End: 2015-07-31Updated: 2016-08-29

Unknown Phase

Analgesic effect of etodolac on neuropathic pain

RecruitingJPRN-UMIN000012665

The University of Tokyoneuropathic pain

Start: 2013-12-24Target: 30Updated: 2025-07-18

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

RecruitingNCT05429970

Memorial Sloan Kettering Cancer CenterEpithelial Ovarian Cancer, Fallopian Tube Cancer, Ovarian Cancer +11

Start: 2022-06-17End: 2026-06-17Target: 35Updated: 2025-05-18